文献速递前列腺癌

转移性激素敏感性前列腺癌治疗格局演变:多西他赛或阿比特龙联合ADT的证据综述

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-12-20

本文综述了在转移性激素敏感性前列腺癌(mHSPC)中,将多西他赛或阿比特龙联合雄激素剥夺治疗(ADT)的随机III期研究。文章描述了CHAARTED、STAMPEDE-多西他赛、GETUG-AFU 15、LATITUDE和STAMPEDE-阿比特龙试验的设计、入选标准与关键结果,并比较了两种联合方案的证据。结论指出,阿比特龙联合泼尼松加ADT已成为多西他赛联合ADT之外的替代标准治疗,正在进行的试验将明确联合还是序贯策略更优。

要点

  • 多西他赛或阿比特龙联合ADT较单用ADT在mHSPC中显示明显生存获益。
  • 阿比特龙联合泼尼松加ADT已成为多西他赛联合ADT之外的替代标准治疗。
  • 联合与序贯使用AR靶向药物和紫杉类化疗的优劣尚待正在进行的试验明确。

核心结论

  • 阿比特龙联合泼尼松加ADT已成为多西他赛联合ADT之外的替代标准治疗,mHSPC管理正在演变。
  • 正在进行的试验应明确在激素敏感阶段初始治疗中,AR靶向药物与紫杉类化疗采用联合还是序贯策略更优。

研究设计与样本

  • 本文为对研究多西他赛或阿比特龙联合ADT治疗mHSPC的随机III期试验的综述。
  • 综述涵盖CHAARTED、STAMPEDE-多西他赛、GETUG-AFU 15、LATITUDE和STAMPEDE-阿比特龙临床试验。

主要发现

  • 2015年CHAARTED和STAMPEDE-多西他赛研究显示,在mHSPC中多西他赛联合ADT较单用ADT带来明显生存获益,改变了标准治疗。
  • 近期LATITUDE和STAMPEDE-阿比特龙试验显示,在该人群中阿比特龙联合泼尼松加ADT带来类似的显著生存改善。
  • 综述描述了上述试验的研究设计、关键入选标准和关键结果,并比较了阿比特龙/泼尼松联合ADT与多西他赛联合ADT的证据。

临床怎么用

  • 文章讨论了在mHSPC中选择多西他赛联合ADT还是阿比特龙联合泼尼松加ADT时应考虑的若干因素。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). In 2015, the CHAARTED and STAMPEDE-Docetaxel studies demonstrated marked survival benefit with the addition of docetaxel to ADT in the mHSPC setting, leading to a change in the standard-of-care for mHSPC. The recent LATITUDE and STAMPEDE-Abiraterone trials showed similar substantial improvement in survival with the addition of abiraterone plus prednisone to ADT in this space. METHODS: We conducted a review of the randomized phase III studies that have investigated either the addition of docetaxel or abiraterone to ADT in patients with mHSPC. RESULTS: We describe the study designs, key eligibility criteria, and key results for the CHAARTED, STAMPEDE-Docetaxel, GETUG-AFU 15, LATITUDE, and STAMPEDE-Abiraterone clinical trials. We compare the data for abiraterone/prednisone plus ADT in mHSPC with the evidence for docetaxel plus ADT in these patients. Finally, we discuss several factors that should be considered when choosing between docetaxel/ADT or abiraterone/prednisone/ADT in mHSPC. CONCLUSIONS: The management of mHSPC is evolving. Abiraterone plus prednisone in addition to ADT has emerged as an alternative standard-of-care to docetaxel plus ADT, and ongoing trials should clarify whether combination vs. sequential approaches with AR-targeting agents and taxane chemotherapy are preferred for initial management in the hormone-sensitive setting.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. McNamara M, Sweeney C, Antonarakis ES, et al. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer Prostatic Dis. 2017. PMID: 29263421. doi:10.1038/s41391-017-0014-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。